MEI Pharma Inc. | Ownership
Companies that own MEI Pharma Inc.
Caxton Corp.
4,400,439
6.19%
4,400,439
18.48%
06/30/2018
BVF Partners LP
3,080,308
4.33%
3,080,308
0.87%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
2,913,091
4.09%
2,913,091
0.84%
06/30/2018
Renaissance Technologies LLC
2,218,813
3.12%
327,500
0.01%
06/30/2018
Sio Capital Management LLC
2,183,986
3.07%
1,249,423
5.04%
06/30/2018
Millennium Management LLC
1,394,790
1.96%
1,384,237
0.01%
06/30/2018
The Vanguard Group, Inc.
1,371,001
1.93%
-83,129
0%
06/30/2018
Acuta Capital Partners LLC
880,087
1.24%
880,087
0.64%
06/30/2018
BlackRock Fund Advisors
493,264
0.69%
10,637
0%
06/30/2018
Walleye Trading Advisors LLC
449,443
0.63%
342,501
0.06%
06/30/2018
| Address |
3611 Valley Centre Drive
San Diego California 92130
United States
|
|
Employees
|
- |
| Website |
http://www.meipharma.com |
| Updated |
07/08/2019 |
| MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. |
